Abstract Background: Steroid-sensitive nephrotic syndrome (SSNS) is the most common form of nephrotic syndrome in childhood. SSNS is considered an autoimmune disease with an established classical human leukocyte antigen (HLA) association; however, the precise etiology of the disease is unclear. In other autoimmune diseases, the identification of loci outside the classical HLA region by genome-wide association studies (GWAS) have provided critical insights into their pathogenesis. Previously conducted GWAS of SSNS have failed to identify non-HLA loci achieving genome-wide significance.
Introduction
Steroid-sensitive nephrotic syndrome (SNSS) is the most common form of nephrotic syndrome in children with an incidence of approximately one to ten per 100,000. 1 The majority of affected children experience a chronic relapsing course. The onset of disease manifestations is commonly associated with a preceding activation of the immune system, typically by an upper respiratory tract infection. 2 As the name implies, SSNS is characterized by a therapeutic response to glucocorticoids, as well as to other immunosuppressants. The apparent triggering of the disease by infection and the therapeutic effect of immunosuppressive treatment have suggested that SSNS is an autoimmune disorder. 3 Investigating the genetic architecture of other autoimmune diseases through genomewide association studies (GWAS) has proved successful in providing insight into their etiology and pathogenesis. Unsurprisingly, a common finding in these studies is the identification of association to the human leukocyte antigen (HLA) region which contains numerous genes critical for the immune system, in particular enabling the distinction between self and foreign. 4 Arguably, however, it is the identification of risk loci outside the HLA locus that can provide the most informative mechanistic insights into the pathogenesis of such diseases.
Prominent examples from nephrology include membranous nephropathy (MN) and IgA nephropathy (IGAN). In MN, GWAS identified association with PLA2R1 suggesting that the antibody formation against the PLA2R1 receptor observed in MN is a causal disease mechanism. 5, 6 Similarly, in IGAN, GWAS have highlighted the important role of the intestinal immune response, as well as IgA1 antibody glycosylation in the pathogenesis of the disease. [7] [8] [9] Three GWAS of SSNS have recently been reported, but in all association at genomewide significance was identified within the HLA region only. [10] [11] [12] We set out to perform a GWAS employing the largest number of ethnically homogenous cases and controls studied to date in an attempt to identify further loci associated with SSNS.
Methods
Full details of all methods can be found in the Supplements.
Cohorts
DNA from pediatric patients diagnosed with SSNS and of reported European ethnicity were utilized in this study. SSNS was defined according to standard clinical criteria. 13 DNA was acquired from the PREDNOS (EudraCT 2010-022489-29) and PREDNOS2 (EudraCT 2012-003476-39) trials, 14 as well as from collaborating clinicians at their affiliated institutions. Informed consent was obtained from all participants and ethical approval was granted by the host institutions. Ethnically matched controls were drawn from publicly available datasets ( Supplementary Figure 1 ). For the replication of our findings, we examined the results of previously published GWAS of SSNS. [10] [11] [12] Genotyping, Quality control and Imputation Isolation of DNA, genotyping, quality control (QC) and imputation were performed using standard procedures. Cases were genotyped by UCL Genomics (Institute of Child Health, UCL, London, UK) on the Infinium Multi-Ethnic Global BeadChip v.A1 (Illumina, CA, USA). Controls had been genotyped on a variety of platforms (for further details see Supplements). [15] [16] [17] Stringent quality control steps for both SNPs and individuals (including missingness, heterozygosity and deviation from Hardy-Weinberg equilibrium) were carried out on cases and controls separately, as well as on the combined cohort ( Supplementary Figure 1 ). Principal component analysis was employed to identify the subset of cases and controls of European ancestry ( Supplementary Figure 4) . The genomic inflation factor (lambda) was calculated to estimate population stratification. Imputation was performed on the combined case-control dataset with Beagle 5.0 (https://faculty.washington.edu/browning/beagle/beagle.html) using only markers passing stringent QC and present in all datasets. 18 
GWAS and conditional analysis
The primary association analysis was performed using logistic regression under an additive model with adjustment for the first ten principal components of ancestry.
Conditional analysis of the lead SNPs was performed using a logistic regression model. regression under an additive model with adjustment for the first ten principal components of ancestry was used to test for association of each HLA allele with SSNS. Conditional analysis of the lead HLA alleles was performed, also using a logistic regression model.
eQTL analysis
Publicly available expression quantitative trait loci (eQTL) databases were queried to ascertain whether variants significantly associated with SSNS were known to influence the expression levels of corresponding gene products in multiple tissues.
Results

Study cohort
DNA 
GWAS results
Our GWAS revealed three loci achieving genome-wide significance ( Figure 1 ). Together, these loci explain approximately 14% of the genetic risk for SSNS. The strongest signal Figure 2A ).
Conditional analysis on rs9273542 decreased the strength of the association such that the minimum p-value achieved at this locus changed to P=4.29×10 -31 for rs2858317, centromeric of HLA-DQB1 ( Figure 2B ). Joint conditioning on rs9273542 and rs2858317 significantly reduced the strength of the association to a minimum p-value of P=2.40×10 -8 at rs3828799 ( Figure 2C ). These results indicate that the association at this locus is driven by at least two independent signals.
Our two lead SNPs (rs9273542 and rs2858317) are in strong linkage disequilibrium with with rs4642516, identified by Jia et al. 12 and with two markers, rs1063348 and rs28366266, identified by Debiec et al.. 11 The strongest association outside the HLA region was with a locus on chromosome 6q22. (previously called FAMF26F) ( Figure 3A ). Genome-wide significance was lost by conditioning on rs2637678 ( Figure 3B ) indicating a single signal is responsible for driving this association.
The third locus to reach genome-wide significance was on chromosome 4q13.3. The lead SNP, rs10518133, is in the intronic region of the gene PARM1 and was associated at P=2.50×10 -8 with OR 1.96 (95% CI=1.57-2.45) ( Figure 4A ). Genome-wide significance was also lost at this locus by conditioning on the lead SNP, indicating a single signal is driving the association ( Figure 4B) . 
eQTL analysis
The three leading SNPs at the CALHM6 locus (rs2637678, rs2637681, rs2858829) exhibit strong cis-eQTL effects in the GTEx database. 21 For all three SNPs, the highest normalized effect size is seen in EBV-transformed lymphocytes (rs2637678: normalized effect size [NES]=0.66, p=7.2×10 -10 ; rs2637681: NES=0.67, p= 1.9×10 -9 ; rs2858829:
NES=0.66, p=3.2×10 -9 ). A strong cis-eQTL effect is also noted in the eQTLgen database from blood (Z-score=43.18, p=3.27×10 -310 ), which also involves the neighboring genes DSE, RWDD1 and NT5DC1. 22 In both databases, the minor allele is associated with increased expression of CALHM6. Of note, no expression of CALHM6 is noted in whole kidney in the GTEx, NephQTL and Human Kidney Atlas Expression (HKAE) databases. 23, 24 HKAE suggests specific expression in glomerulus, but this could not be confirmed in the other databases.
No significant eQTLs were found for rs10518133 (tagging the PARM1 locus) in any tissue in the GTEx database, but in eQTLgen, the risk allele is associated with significant downregulation of PARM1.
Discussion
This study has confirmed the association of SSNS with the HLA locus and identified two additional loci on chromosome 6 and chromosome 4 achieving genome-wide significance.
HLA locus
By far the most associations identified by GWAS of human diseases are located in the HLA region. 25 The vast majority of these phenotypes are autoimmune or infectious diseases. The necessity for an appropriate and ever evolving response to infection drives variation in HLA peptide binding grooves and some of these variants can lead to inappropriate responses against antigens of the host. 26 Thus, unsurprisingly and consistent with previous studies, the strongest signal for association with SSNS we identified was in the HLA region. [10] [11] [12] The lead SNP, rs9273542 (Table 1) , is located within the HLA-DR/DQ region, specifically HLA-DQB1.
Imputation of HLA alleles identified that HLA-DQA1*02:01 and HLA-DRB1*07:01 are associated with the strongest risk, whereas HLA-DQA1*01 appears to be independently protective. HLA-DRB1*13 (p=2.41×10 -14 ) is also protective, which is similar to the results of Jia et al. who showed in an Asian population that HLA-DRB1*13:02 and HLA-DQB1*06:04 have protective effects. 12 In the study by Debiec et al., serial conditional analysis of the HLA association revealed an independently associated SNP located within BTNL2 (rs9348883), although this did not reach genome-wide significance. 11 We were unable to confirm an independent association with this gene, which may reflect the different ethnicities analyzed, as the BTNL2 signal was primarily driven by the African cohort in that study.
Associations outside the HLA region
The adaptive immune response is triggered by HLA peptide -epitope binding, but is modulated by regulatory mechanisms, elements of which are encoded in non-HLA genes. 4 Arguably, it is the identification of these genes that can provide the most informative insights into the complex architecture of the dysregulated immune response in specific diseases. We here describe the discovery of two loci outside the HLA region achieving genome-wide significant associations with SSNS.
CALHM6 association (6q22.1)
The strongest signal outside the HLA region is on chromosome 6q22.1 and the lead SNP, rs2637678 (Table 1) , is located very near the gene CALHM6 (Calcium Homeostasis
Modulator Family Member 6), previously also annotated as FAM26F or INAM (IRF-3-dependent NK-activating molecule). 27 Of note, this locus had been identified as a potential signal in SSNS by Debiec et al., but did not reach genome-wide significance. 11 The 6q22.1 SNP reported by Debiec et al. is identical to one of the lead SNPs identified in this study (rs2858829) and was associated with a p-value of 6.8×10 -8 . Importantly, the existence of this published suggestive association at rs2858829 provides independent confirmatory evidence for our genome-wide significant finding.
The apparent absence of expression of CALHM6 in the kidney is in contrast to the high expression in lymphocytes and consistent with the notion that impaired immune regulation is a key risk factor for the development of SSNS. Indeed, CALHM6 is thought to have an important role in the regulation of the immune system, by facilitating interactions and potential synapses between immune cells. 28 It is differentially regulated in response to various immune stimuli, especially interferon-, with predicted interferon-stimulated response element (ISRE) and signal transducer and initiator of transcription (STAT) binding sites in its promoter. 29 Members of the CALHM family are thought to belong to the ATP-release channel superfamily. 30 CALHM6 is highly expressed in lymphocytes and ATP is a recognized trigger for apoptosis, including of immune cells. 31, 32 A key effect of glucocorticoids on the immune system is the induction of lymphocyte apoptosis. 33 Thus, CALHM6 may play a role in mediating this effect and impaired CALHM6 function may exacerbate an exaggerated immune response, leading to SSNS, which can be suppressed by pharmacologic doses of glucocorticoids. Of note, the same locus with the same risk allele, has been previously associated with another autoimmune disease highly sensitive to steroid treatment, ulcerative colitis, providing further evidence for the importance of CALHM6 in immune response regulation. 34
CALHM6 eQTL analysis
We performed an eQTL analysis to further assess potential associations between our identified variants and gene expression. 35 Of note, for the lead variants in CALHM6, the presence of the minor allele is protective against SSNS, so that the major allele is the risk allele and enriched in patients. Interestingly, the lead variant (rs2637678) at the CALHM6 locus is a known eQTL and the risk allele is associated with decreased CALHM6 expression. This is consistent with the hypothesis that the presence of the risk allele may impair lymphocyte apoptosis and thus lead to less effective downregulation of an immune response.
However, it is important to note that GWAS identify variants that represent a haploblock rather than a specific gene associated with the disease. This is best illustrated by the initial controversy over the association of MYH9 versus APOL1 with non-diabetic kidney disease in African Americans. 36 Thus, it is possible that another gene in the haploblock with CALHM6 may actually be causally associated. Indeed, in the eQTLGen database, rs2637678 has highly significant eQTL effects also on neighboring genes. CALHM6 was prioritised based on its proximity to the GWAS signal and its known function but further studies will be required to establish with certainty if this is indeed the gene responsible for driving the observed association.
PARM1 association (4q13.3)
In addition, we found a genome-wide significant association with a locus on chromosome 4q13.3 (lead SNP rs10518133, P=2.50×10 -8 , OR=1.96), which is located within the gene PARM1 (Prostate androgen-regulated mucin-like protein 1). Interestingly, this locus is Figure 3 ). This hot spot is at least equally strong in African populations (supplemental table 2), so that the different ethnicities cannot explain the separation of this locus between the previous and our study.
Limitations
Our study has several limitations. First, only limited clinical information on our patients is available. However, the majority of cases were obtained through two clinical trials (PREDNOS and PREDNOS2) which recruited from more than a hundred pediatric units across the UK and it is thus highly unlikely that our patient cohort is substantially different from other SSNS cohorts. Indeed, the available data, such as the 2:1 male:female ratio, matches perfectly with published data. 13 Next, we used publicly available genotype data for controls, so that data from different genotyping platforms needed to be combined. As detailed in supplementary figure 1, this led to a limited set of overlapping genotyped SNP and the majority of SNPs used in our final analysis were imputed. However, imputation has become an accepted tool in GWAS and the fact that the analysis with genotyped markers only (supplementary figure 5) identifies the same loci, albeit with higher p-values, provides strong evidence that these loci are genuinely associated with the phenotype and have not been identified due to imputation artefacts. 37 The most important limitation, however, is the lack of a replication cohort. The independent identification of loci at both 6q22.1 and 4q13.3 by Debiec et al. provides strong confirmatory evidence for our results. Yet, as detailed above, the lead SNP at 4q13.3 identified in that study is separated from our lead SNP by a recombination hotspot.
It therefore remains to be determined whether this region is truly associated with SSNS or not and, if so, if these loci are independent from each other. Moreover, Debiec et al.
did not provide detailed information on the risk allele at 6q22.1 and we are thus unable to assess whether the allelic effect is identical in both studies. Further independent replication is thus needed to confirm the discovery of these loci.
Conclusions
Our study identifies two loci outside the HLA-region with genome-wide significant association with SSNS and thus provides important insight into the pathogenesis of SSNS. As CALHM6 is implicated in regulating the immune response to infection, this may provide an explanation for the typical triggering of disease onset by infections. Further studies are needed to provide independent replication of our findings and to investigate the precise mechanisms and whether these could be amenable to specific treatments.
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